Search clinical trials for: Copaxone

Total 56 results

Riphah International University

Active, not recruiting

Effect of Moringa Oleifera Mouthwash

Orthodontic Appliance Complication

Pakistan
Centocor, Inc.
Centocor BV

Completed

A Safety and Efficacy Study of CNTO1275 in Patients With Multiple Sclerosis

Multiple Sclerosis
Vedic Lifesciences Pvt. Ltd.

Recruiting

A Study to Explore the Effect of Moringa Oleifera (E-HS-01) on Flow Mediated Dilatation and Hemodynamics

Endothelial Function

India
Federal University of São Paulo

Unknown

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation

Diabetic Retinopathy

Brazil
The New York Eye & Ear Infirmary

Suspended

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration

Dry Age Related Macular Degeneration

United States
University of Medicine and Dentistry of New Jersey

Completed

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI (BECOME)

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® (CONFIDENCE)

Multiple Sclerosis

United States, Argentina, Austria, Belgium, Croatia, Finland, France, Germany, Ireland, Italy, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Optic Neuritis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.

Relapsing Remitting Multiple Sclerosis
University of Kansas Medical Center

Active, not recruiting

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Basal Cell Carcinoma | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Sheba Medical Center

Unknown

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Rett Syndrome

Israel
Montefiore Medical Center
Rett Syndrome Research Trust

Completed

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Rett Syndrome

United States
Amphia Hospital
Sanofi; TEVA Pharmachemie

Unknown

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) (OCTIMS)

Multiple Sclerosis

Netherlands
Kaplan Medical Center

Unknown

Copaxone in Age Related Macular Degeneration

Macular Degeneration

Israel
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.

Multiple Sclerosis
Takeda

Active, not recruiting

Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"

Multiple Sclerosis

Japan
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
University of Oklahoma
Pfizer

Completed

Treatment of Upper Extremity Deep-Vein Thrombosis

Deep-Vein Thrombosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)

Relapsing Remitting Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Poland, Romania, Russian Federation, South Africa, Ukraine, United Kingdom
Teva Neuroscience, Inc.

Completed

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)

Relapsing-Remitting Multiple Sclerosis

United States, Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Greece, Latvia, Macedonia, The Former Yugoslav Republic of, Mexico, Moldova, Republic of, Montenegro, Poland, Romania, Russian... and more
University of California, San Francisco
National Multiple Sclerosis Society; Teva Neuroscience, Inc.

Completed

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis

Multiple Sclerosis

United States
Synthon BV

Completed

Efficacy and Safety of GTR in Comparison to Copaxone® (GATE)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Georgia, Germany, Italy, Mexico, Moldova, Republic of, Poland, Romania, Russian Federation, Serbia, South Africa, Ukraine, United Kingdom
Hadassah Medical Organization
Weizmann Institute of Science

Completed

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure (Copaxone)

Heart Failure | Inflammatory Response | Acute Decompensated Heart Failure | Cytokine Storm

Israel
Teva Neuroscience, Inc.

Completed

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®

Multiple Sclerosis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (PreCISe)

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Tolerability of Glatiramer Acetate (GLACIER)

Relapsing-Remitting Multiple Sclerosis

United States
University of Oklahoma
Pfizer

Completed

Management of Superficial Thrombophlebitis

Superficial Thrombophlebitis | Upper Extremity Superficial Thrombophlebitis | Lower Extremity Superficial Thrombophlebitis

United States
University at Buffalo
Teva Neuroscience, Inc.

Completed

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Multiple Sclerosis

United States
Singapore Eye Research Institute

Unknown

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Glaucoma, Angle-closure, Primary, Acute

Singapore
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Relapsing Remitting Multiple Sclerosis
University of Colorado, Denver
Rocky Mountain MS Research Group, LLC

Completed

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate (GATEWAYII)

Multiple Sclerosis

United States
Neurognostics

Terminated

An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis

Relapsing-Remitting Multiple Sclerosis

United States
Tanta University

Unknown

Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?

Primary Bacterial Peritonitis

Egypt
Teva Neuroscience, Inc.

Completed

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients (ENCORE)

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Relapse Remitting Multiple Sclerosis
Biocad

Completed

Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis
EMD Serono

Terminated

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)

Relapsing Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, Italy, Mexico, Russian Federation, South Africa, Spain, Turkey, Hungary, Poland, Ukraine, Finland, United Kingdom, Greece, Serbia
University of California, Los Angeles
Johns Hopkins University; University of Colorado, Denver; Mayo Clinic; University... and other collaborators

Completed

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) (Estriol-MS)

Relapsing Remitting Multiple Sclerosis

United States, Canada
Novartis Pharmaceuticals

Terminated

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone (ASSESS)

Relapsing-remitting Multiple Sclerosis (RRMS)

United States, Canada, Mexico, Brazil, Puerto Rico, Argentina, Chile
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate (ASSERT)

Relapsing Remitting Multiple Sclerosis
Bayer

Completed

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Multiple Sclerosis, Relapsing-Remitting

Belgium, Israel, Sweden, United States, France, Switzerland, Ireland, Canada, Australia, Brazil, Austria, Poland, Germany, Hungary, Netherlands, Russian Federation, Spain, Argentina, Slovenia, Greece, Finland, Denmark, Ukraine, Italy, L... and more
EMD Serono
Pfizer

Completed

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

United States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
Biogen
Elan Pharmaceuticals

Terminated

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)

Relapsing Remitting Multiple Sclerosis

United States, Czech Republic, Italy, Spain, Sweden, Latvia, Finland, Hungary, Poland, Slovenia, Australia, Canada, France
Novartis Pharmaceuticals

Completed

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change (EPOC)

Relapsing Remitting Multiple Sclerosis

Italy
Novartis Pharmaceuticals

Completed

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (EPOC)

Relapsing Forms of Multiple Sclerosis

United States, Canada, Puerto Rico
Nancy Hammond, MD
Kansas City Area Life Sciences Institute, Inc.

Completed

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Multiple Sclerosis | Low Bone Density

United States
Sanofi

Completed

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Germany, United Kingdom, Austria, Italy
Queen Mary University of London
University of Southampton; Ministry of Health and Child Welfare, Zimbabwe; CI...

Active, not recruiting

Child Health, Agriculture and Integrated Nutrition (CHAIN)

Stunting

Zimbabwe
Biogen

Withdrawn

Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis

Search clinical trials for: Copaxone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations